

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 22, 2019**

---

**UROGEN PHARMA LTD.**

(Exact name of registrant as specified in its charter)

---

**Israel**  
(State or other jurisdiction  
of incorporation)

**001-38079**  
(Commission  
File Number)

**98-1460746**  
(IRS Employer  
Identification No.)

**499 Park Avenue**  
**New York, New York**  
(Address of principal executive offices)

**10022**  
(Zip Code)

**Registrant's telephone number, including area code: +1 (646) 768-9780**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Ordinary Shares, par value NIS0.01 per share</b>	<b>URGN</b>	<b>The Nasdaq Stock Market LLC</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 7.01 Regulation FD Disclosure.**

On November 15, 2019, UroGen Pharma Ltd. (the “Company”), as sublandlord, entered into a sublease (the “Sublease”) with a group of law offices, as subtenants, relating to the sublease of approximately 4,900 square feet of office space located at 10900 Wilshire Blvd., Los Angeles, California 90024 (the “Premises”). The term of the Sublease commences on January 1, 2020 and expires on March 8, 2024.

The Company’s remaining minimum lease obligation under the master lease for the Premises is approximately \$1.2 million. The aggregate base rent due to the Company over the term of the Sublease is approximately \$1.0 million.

**Item 9.01 Financial Statements and Exhibits.**

(d)

**Exhibit  
Number****Description**

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 22, 2019

**UROGEN PHARMA LTD.**

By: /s/ Peter Pfreunds Schuh

Peter Pfreunds Schuh  
Chief Financial Officer